查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
封面
市場調查報告書
商品編碼
1571433

地中海貧血市場規模、佔有率和趨勢分析報告：按治療方法、類型、地區和細分市場預測，2024-2030 年

Thalassemia Market Size, Share & Trends Analysis Report By Treatment (Iron Chelating Drugs, Erythroid Maturation Agents, Stem Cell Therapy), By Type (Alpha Thalassemia, Beta Thalassemia), By Region, And Segment Forecasts, 2024 - 2030
出版日期: | 出版商: Grand View Research | 英文 80 Pages | 商品交期: 2-10個工作天內

價格
簡介目錄

地中海貧血市場成長與趨勢：

Grand View Research, Inc.最新報告顯示，到2030年，全球地中海貧血市場規模預計將達到14.301億美元，2024年至2030年複合年成長率為7.8%。

對通用治療方法的需求增加、對該疾病的認知提高以及技術進步可能會增加基因療法的採用。

地中海貧血是一組遺傳性血液疾病，身體產生異常血紅蛋白，導致紅血球遭到破壞。這最終會導致貧血。地中海貧血主要有兩種：α地中海貧血和BETA地中海貧血，後者更嚴重。 BETA地中海型貧血是一種體染色體隱性遺傳疾病，在美國相對罕見。

地中海貧血盛行率的增加預計將推動市場成長。儘管技術不斷進步，但對可靠治療方案的需求仍未被滿足。地中海貧血的治療主要限於定期輸血和鐵螯合療法。大多數治療地中海貧血的藥物可以治療貧血、鐵超載和維生素缺乏等症狀和副作用。然而，基因療法正成為這種疾病的可靠治療方法。

據報道，地中海貧血的盛行率多年來在各個地區逐漸增加。這可能是因為人口遷移、婚姻以及遺傳和環境因素驅動了該疾病及其影響。

地中海貧血市場報告亮點

  • 鐵螯合藥物細分市場在 2023 年佔據最大收益佔有率，達到 52.7%。地中海貧血患者經常需要定期輸血，這會導致體內鐵超載。
  • BETA-地中海型貧血佔2023年最大銷售佔有率，為71.2%。 BETA-地中海貧血診斷技術和治療方案的不斷進步顯著改善了患者的預後。
  • 北美地中海貧血市場主導全球市場，2023年銷售佔有率為42.8%。

目錄

第1章調查方法與範圍

第 2 章執行摘要

第3章地中海貧血市場變數、趨勢與範圍

  • 市場介紹/系統展望
  • 市場規模及成長前景
  • 市場動態
    • 市場促進因素分析
    • 市場限制因素分析
  • 地中海型貧血市場分析工具
    • 波特的分析
    • PESTEL分析

第4章地中海貧血市場：治療評估與趨勢分析

  • 細分儀表板
  • 地中海型貧血市場：2023 年和 2030 年治療變化分析
  • 鐵螯合藥物
  • 紅色甲狀腺成熟者
  • 幹細胞療法
  • 其他

第5章地中海貧血市場：類型估計和趨勢分析

  • 細分儀表板
  • 地中海貧血市場：2023 年和 2030 年按類型變化分析
  • α地中海貧血
  • BETA地中海型貧血

第6章地中海貧血市場：區域估計與趨勢分析

  • 2023 年及 2030 年地中海貧血市場佔有率（按地區）
  • 北美洲
    • 美國
    • 加拿大
    • 墨西哥
  • 歐洲
    • 英國。
    • 德國
    • 法國
    • 義大利
    • 西班牙
    • 丹麥
    • 瑞典
    • 挪威
  • 亞太地區
    • 日本
    • 中國
    • 印度
    • 澳洲
    • 韓國
    • 泰國
  • 拉丁美洲
    • 巴西
    • 阿根廷
  • 中東和非洲
    • 南非
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國
    • 科威特

第7章 競爭格局

  • 主要市場參與企業的最新趨勢和影響分析
  • 公司分類
  • 企業熱力圖分析
  • 公司簡介
    • CHIESI Farmaceutici SpA
    • Bristol-Myers Squibb Company
    • Sun Pharmaceutical Industries Ltd.
    • Cipla
    • Fresenius Kabi AG
    • Novartis Pharmaceuticals Corporation
    • Apotex Inc.
    • bluebird bio, Inc.
簡介目錄
Product Code: GVR-2-68038-349-2

Thalassemia Market Growth & Trends:

The global thalassemia market size is expected to be valued at USD 1,430.1 million by 2030, as per a new report by Grand View Research, Inc., exhibiting a CAGR of 7.8% from 2024 to 2030. Increase in demand for a universal cure, rise in awareness about the disease, and technological advancements are likely to increase the adoption of gene therapies.

Thalassemia is a general term for a group of inheritable blood disorders, in which the body produces abnormal hemoglobin, resulting in the destruction of red blood cells. This ultimately leads to anemia. There are two main types of thalassemia: alpha-thalassemia and beta-thalassemia, the latter being more serious. Beta-thalassemia is a common autosomal recessive disorder worldwide and it is relatively rare in the U.S.

Increase in the incidence of thalassemia is anticipated to fuel market growth. Despite technological advancements, the unmet need for a reliable treatment option still exists. Treatment of thalassemia is mostly restricted to regular blood transfusions and iron chelation therapy. Drugs prescribed for thalassemia mostly cure symptoms and side effects such as anemia, iron overload, and vitamin deficiency. However, gene therapy is emerging as a reliable treatment option for the disease.

Prevalence of thalassemia is reported to increase gradually over the years across different regions. This can be attributed to population migration, intermarriages, and genetic and environmental factors prompting the condition and its implications.

Thalassemia Market Report Highlights:

  • The iron chelating drugs segment held the largest revenue share of 52.7% in 2023. Patients with thalassemia often require regular blood transfusions, which can lead to iron overload in the body.
  • The beta thalassemia held the largest revenue share of 71.2% in 2023. Ongoing advancements in diagnostic techniques and treatment options for beta thalassemia have significantly improved patient outcomes.
  • North America thalassemia market dominated the global market with a revenue share of 42.8% in 2023.

Table of Contents

Chapter 1. Methodology and Scope

  • 1.1. Market Segmentation and Scope
  • 1.2. Market Definitions
  • 1.3. Research Methodology
    • 1.3.1. Information Procurement
    • 1.3.2. Information or Data Analysis
    • 1.3.3. Market Formulation & Data Visualization
    • 1.3.4. Data Validation & Publishing
  • 1.4. Research Scope and Assumptions
    • 1.4.1. List of Data Sources

Chapter 2. Executive Summary

  • 2.1. Market Outlook
  • 2.2. Segment Outlook
  • 2.3. Competitive Insights

Chapter 3. Thalassemia Market Variables, Trends, & Scope

  • 3.1. Market Introduction/Lineage Outlook
  • 3.2. Market Size and Growth Prospects (USD Million)
  • 3.3. Market Dynamics
    • 3.3.1. Market Drivers Analysis
    • 3.3.2. Market Restraints Analysis
  • 3.4. Thalassemia Market Analysis Tools
    • 3.4.1. Porter's Analysis
      • 3.4.1.1. Bargaining power of the suppliers
      • 3.4.1.2. Bargaining power of the buyers
      • 3.4.1.3. Threats of substitution
      • 3.4.1.4. Threats from new entrants
      • 3.4.1.5. Competitive rivalry
    • 3.4.2. PESTEL Analysis
      • 3.4.2.1. Political landscape
      • 3.4.2.2. Economic and Social landscape
      • 3.4.2.3. Technological landscape
      • 3.4.2.4. Environmental landscape
      • 3.4.2.5. Legal landscape

Chapter 4. Thalassemia Market: Treatment Estimates & Trend Analysis

  • 4.1. Segment Dashboard
  • 4.2. Thalassemia Market: Treatment Movement Analysis, 2023 & 2030 (USD Million)
  • 4.3. Iron Chelating Drugs
    • 4.3.1. Iron Chelating Drugs Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.4. Erythyroid Maturation Agents
    • 4.4.1. Erythyroid Maturation Agents Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.5. Stem Cell therapy
    • 4.5.1. Stem Cell Therapy Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 4.6. Others
    • 4.6.1. Others Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 5. Thalassemia Market: Type Estimates & Trend Analysis

  • 5.1. Segment Dashboard
  • 5.2. Thalassemia Market: Type Movement Analysis, 2023 & 2030 (USD Million)
  • 5.3. Alpha Thalassemia
    • 5.3.1. Alpha Thalassemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 5.4. Beta Thalassemia
    • 5.4.1. Beta Thalassemia Market Revenue Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 6. Thalassemia Market: Regional Estimates & Trend Analysis

  • 6.1. Thalassemia Market Share, By Region, 2023 & 2030 (USD Million)
  • 6.2. North America
    • 6.2.1. North America Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.2. U.S.
      • 6.2.2.1. U.S. Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.3. Canada
      • 6.2.3.1. Canada Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.2.4. Mexico
      • 6.2.4.1. Mexico Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.3. Europe
    • 6.3.1. Europe Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.2. UK.
      • 6.3.2.1. UK Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.3. Germany
      • 6.3.3.1. Germany Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.4. France
      • 6.3.4.1. France Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.5. Italy
      • 6.3.5.1. Italy Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.6. Spain
      • 6.3.6.1. Spain Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.7. Denmark
      • 6.3.7.1. Denmark Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.8. Sweden
      • 6.3.8.1. Sweden Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.3.9. Norway
      • 6.3.9.1. Norway Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.4. Asia Pacific
    • 6.4.1. Asia Pacific Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.2. Japan
      • 6.4.2.1. Japan Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.3. China
      • 6.4.3.1. China Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.4. India
      • 6.4.4.1. India Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.5. Australia
      • 6.4.5.1. Australia Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.6. South Korea
      • 6.4.6.1. South Korea Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.4.7. Thailand
      • 6.4.7.1. Thailand Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.5. Latin America
    • 6.5.1. Latin America Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.2. Brazil
      • 6.5.2.1. Brazil Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.5.3. Argentina
      • 6.5.3.1. Argentina Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
  • 6.6. Middle East and Africa
    • 6.6.1. Middle East and Africa Thalassemia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.2. South Africa
      • 6.6.2.1. South Africa Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.3. Saudi Arabia
      • 6.6.3.1. Saudi Arabia Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.4. UAE
      • 6.6.4.1. UAE Market Estimates and Forecasts, 2018 - 2030 (USD Million)
    • 6.6.5. Kuwait
      • 6.6.5.1. Kuwait Market Estimates and Forecasts, 2018 - 2030 (USD Million)

Chapter 7. Competitive Landscape

  • 7.1. Recent Developments & Impact Analysis by Key Market Participants
  • 7.2. Company Categorization
  • 7.3. Company Heat Map Analysis
  • 7.4. Company Profiles
    • 7.4.1. CHIESI Farmaceutici S.p.A.
      • 7.4.1.1. Participant's Overview
      • 7.4.1.2. Financial Performance
      • 7.4.1.3. Product Benchmarking
      • 7.4.1.4. Recent Developments/ Strategic Initiatives
    • 7.4.2. Bristol-Myers Squibb Company
      • 7.4.2.1. Participant's Overview
      • 7.4.2.2. Financial Performance
      • 7.4.2.3. Product Benchmarking
      • 7.4.2.4. Recent Developments/ Strategic Initiatives
    • 7.4.3. Sun Pharmaceutical Industries Ltd.
      • 7.4.3.1. Participant's Overview
      • 7.4.3.2. Financial Performance
      • 7.4.3.3. Product Benchmarking
      • 7.4.3.4. Recent Developments/ Strategic Initiatives
    • 7.4.4. Cipla
      • 7.4.4.1. Participant's Overview
      • 7.4.4.2. Financial Performance
      • 7.4.4.3. Product Benchmarking
      • 7.4.4.4. Recent Developments/ Strategic Initiatives
    • 7.4.5. Fresenius Kabi AG
      • 7.4.5.1. Participant's Overview
      • 7.4.5.2. Financial Performance
      • 7.4.5.3. Product Benchmarking
      • 7.4.5.4. Recent Developments/ Strategic Initiatives
    • 7.4.6. Novartis Pharmaceuticals Corporation
      • 7.4.6.1. Participant's Overview
      • 7.4.6.2. Financial Performance
      • 7.4.6.3. Product Benchmarking
      • 7.4.6.4. Recent Developments/ Strategic Initiatives
    • 7.4.7. Apotex Inc.
      • 7.4.7.1. Participant's Overview
      • 7.4.7.2. Financial Performance
      • 7.4.7.3. Product Benchmarking
      • 7.4.7.4. Recent Developments/ Strategic Initiatives
    • 7.4.8. bluebird bio, Inc.
      • 7.4.8.1. Participant's Overview
      • 7.4.8.2. Financial Performance
      • 7.4.8.3. Product Benchmarking
      • 7.4.8.4. Recent Developments/ Strategic Initiatives